Google
AGMB Stock Price & Analysis — Agomab Therapeutics NV American Depositary Shares (Healthcare >> Biotechnology)
AGMB FAQ
What is AGMB's ROE?
Agomab Therapeutics NV American Depositary Shares reports a Return on Equity (ROE) of -27.81%.
What is AGMB's dividend yield?
Agomab Therapeutics NV American Depositary Shares offers a dividend yield of 0.00%.
What is AGMB's Quality Score?
Our AI rates AGMB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AGMB?
Our AI Timing Score for AGMB is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AGMB belong to?
Agomab Therapeutics NV American Depositary Shares is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
AGMB AI Analysis Summary
Our AI summary for AGMB: Agomab Therapeutics NV American Depositary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -27.81%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 14.73
Price
1.21
(8.95%)
Day Change
|
|
|---|
AGMB, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.73 |
| PBV / Sector |
4.53 / 44,022.72
|
| Earning Per Share | -0.90 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
0.92 M
GREAT
|
| Average 1W Daily Value |
1.03 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-05 07:59:47 |
| Symbol | AGMB |
| Name | AGOMAB THERAPEUTICS NV AMERICAN DEPOSITARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 49.25 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 665.83 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Posthoflei 1/6, Antwerp, Belgium, 2600
Phone: 32 3 318 91 70
Website: https://www.agomab.com
Employees: 62
Sector: Healthcare >> Biotechnology
Description: AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap